Soundwatch Capital LLC Invests $607,000 in The Cooper Companies, Inc. $COO

Soundwatch Capital LLC purchased a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 853,002 shares of the medical device company’s stock, valued at approximately $607,000. Soundwatch Capital LLC owned approximately 0.43% of Cooper Companies at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Zions Bancorporation National Association UT bought a new position in Cooper Companies in the 1st quarter worth about $33,000. J.Safra Asset Management Corp raised its holdings in Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Cooper Companies in the first quarter worth approximately $40,000. Assetmark Inc. grew its holdings in shares of Cooper Companies by 357.8% during the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after buying an additional 483 shares during the last quarter. Finally, Allworth Financial LP increased its position in shares of Cooper Companies by 36.6% during the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after acquiring an additional 257 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Performance

Shares of COO opened at $75.47 on Friday. The firm has a market capitalization of $15.00 billion, a P/E ratio of 37.18, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $106.63. The business has a fifty day moving average of $70.15 and a 200 day moving average of $71.98.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the firm posted $0.96 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has approved a share repurchase program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Robert W. Baird lowered their price objective on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, August 28th. Stifel Nicolaus decreased their price target on Cooper Companies from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, August 28th. Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, August 28th. Piper Sandler reduced their price objective on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a report on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their target price on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.77.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, EVP Brian G. Andrews purchased 1,525 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were acquired at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the transaction, the executive vice president owned 22,191 shares of the company’s stock, valued at approximately $1,457,504.88. The trade was a 7.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were acquired at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the purchase, the director directly owned 5,777 shares in the company, valued at approximately $395,089.03. The trade was a 52.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 17,975 shares of company stock valued at $1,216,346 in the last quarter. Insiders own 1.98% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.